Monomeric myeloperoxidase is a specific biomarker for early-stage ovarian cancer

• Published in: Biomarkers 2023-12, Vol.28 (7), p.663-671
• Main Authors: Saed, Ghassan M, Nawaz, Asad, Alvero, Ayesha A, Harper, Amy K, Morris, Robert T
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor; Female; Humans; Ovarian Neoplasms - diagnosis; Peroxidase - metabolism
• ISSN: 1354-750X; 1366-5804
• DOI: 10.1080/1354750X.2023.2284106

Ovarian cancer cells are known to express myeloperoxidase (MPO), an oxidant-producing enzyme with a 150 kDa homodimer, consisting of two identical monomers connected by a disulfide bond. Here, we aim to validate monomeric MPO (mMPO) as a biomarker for the early detection of ovarian cancer. Human ovarian cancer cells, sera from patients at various stages, sera from non-cancer inflammatory gynecological diseases, and healthy volunteers were used. Monomeric and dimeric MPO were measured by ELISA. Receiver operating curves were used to compare the predictive powers of serum dimeric and monomeric MPO to discriminate between samples. The expression of MPO was unique to ovarian cancer cells. Specifically, mMPO was found to be the only form of MPO in all ovarian cancer cell lines. Intriguingly, mMPO was detected in the sera from all patients with ovarian cancer at various stages, but not from healthy individuals. Serum mMPO discriminated between early-stage ovarian cancer, healthy controls, and benign inflammatory gynecologic disorders. In addition, mMPO discriminated between the early and late stages of the disease. This work highlights mMPO as a potential biomarker for early detection of ovarian cancer, which is critically needed.